Orionn, a pharmaceutical company, has announced an improvement in its financial results for October-September compared to the previous year. The company’s operating profit increased to 92.9 million euros from 40.7 million euros in the same period last year, surpassing analyst forecasts.
One of the reasons for this improvement was a 30.7 million euro installment related to the transfer of the insurance portfolio of Orion Pension Foundation’s B section. Adjusted for this item, the result still showed improvement from the previous year.
In addition, turnover for the quarter was 321.1 million euros, higher than the estimated 318.9 million euros and the 294.5 million euros from the previous year. Earnings per share also increased, reaching 0.54 euros per share compared to the expected 0.43 euros.
The board of directors has proposed a dividend of 1.62 euros per share for the last fiscal year